Contrasting PRA Health Sciences (PRAH) and Redpoint Bio (RPBC)

PRA Health Sciences (NASDAQ:PRAH) and Redpoint Bio (OTCMKTS:RPBC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Earnings and Valuation

This table compares PRA Health Sciences and Redpoint Bio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PRA Health Sciences $2.87 billion 1.97 $153.90 million $3.93 21.88
Redpoint Bio N/A N/A N/A N/A N/A

PRA Health Sciences has higher revenue and earnings than Redpoint Bio.

Institutional and Insider Ownership

98.1% of PRA Health Sciences shares are owned by institutional investors. 1.0% of PRA Health Sciences shares are owned by company insiders. Comparatively, 11.5% of Redpoint Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares PRA Health Sciences and Redpoint Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PRA Health Sciences 5.50% 26.87% 8.39%
Redpoint Bio N/A N/A N/A

Analyst Ratings

This is a breakdown of current ratings and target prices for PRA Health Sciences and Redpoint Bio, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PRA Health Sciences 0 4 5 0 2.56
Redpoint Bio 0 0 0 0 N/A

PRA Health Sciences presently has a consensus price target of $114.25, indicating a potential upside of 32.88%. Given PRA Health Sciences’ higher possible upside, equities research analysts plainly believe PRA Health Sciences is more favorable than Redpoint Bio.

Summary

PRA Health Sciences beats Redpoint Bio on 7 of the 8 factors compared between the two stocks.

About PRA Health Sciences

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardio metabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.

About Redpoint Bio

Redpoint Bio Corporation, a development stage biotechnology company, focuses on the development of healthier foods and new approaches for the treatment of diabetes and obesity by understanding the biology of taste and its relationship to metabolism, satiety, and diabetes. It enters into a license and commercialization agreement with International Flavors and Fragrances Inc. for the development, manufacture, use, and commercialization of RP44, which is a component of the stevia plant that works as a sweetness enhancer amplifying the existing sugary sweetness in a food or beverage. The company is based in Philadelphia, Pennsylvania.

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.